Life Sciences Executive Christian Darabant Tapped to Lead Hurel's Expansion

Executive Team Expanded to Support Demand for Hurel's Robust Liver Models

North Brunswick, NJ. – Hurel Corporation announced that Christian Darabant has joined the company as Executive Vice President and Chief Operating Officer. Having started his career as an R&D chemist before moving into executive roles, Chris brings to Hurel more than twenty years’ experience leading commercial operations in positions of increasing responsibility at Sekisui Xenotech, Absorption Systems and, most recently, at Frontage Laboratories.

“Hurel offers a superlatively valuable platform for the elucidation of lead compounds, which directly aligns with my passion for furthering human health,” said Darabant. “Safety and DMPK prediction for early-phase therapeutic entities involves a complex cascade of studies. Hurel’s highly insightful, human-relevant model improves in vitro to in vivo correlation, reduces false positives, and most importantly, reduces the risks of late-stage candidate attrition. I am honored to join Hurel, which is brilliantly positioned to support biopharmaceutical research with advanced, more usefully translational data, yielding faster timelines and lowering over-all drug development costs.”

Hurel CEO Rob Freedman commented, “Chris is a customer advocate and a great team-builder, whose effectiveness may be seen reflected in the corporate growth he’s produced in one situation after the next throughout his career. He is just the individual we need to lead Hurel’s next stage. It’s my pleasure to welcome him as a colleague.”

About Hurel

Hurel Corporation is a world-leading provider of patented, primary hepatocyte-based microlivers and microfluidic cell-based assay platforms. Distinguished by their high, stable, and long-enduring levels of metabolic competency, Hurel's products set the current state of the art in DILI prediction, in screening compounds against hepatitis B virus and other liver diseases, and in assessing such pharmacokinetic attributes as clearance rates, metabolites generated, transport effects, reaction phenotypes, and propensity for drug-drug interactions. Hurel's products are available using primary hepatocytes drawn from the human species or, alternatively, from any of nine other preclinical species, and are offered both in single-species formats and in multispecies “zoo plates™” that facilitate interspecies comparison. Utilizing its patent-pending method of packaging its microlivers “warm” for intercontinental air shipment, Hurel delivers its products “plug-and-play ready” to pharmaceutical and biotech researchers worldwide. Hurel also offers in vitro safety- and DMPK-directed contract research services based on its microliver products. For more information please visit www.hurelcorp.com.

Contact:
HUREL CORPORATION
Alvy Gallo 310.652.5900 agallo@hurelcorp.com